MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives

Figure 3

Chronic inflammation as the driving force for clonal evolution in MPNs. Tumor burden and comorbidity burden are illustrated for patients with JAK2V617F positive MPNs. Comorbidity burden increases from early disease stage (ET/PV) to the accelerated phase with myelofibrotic and leukemic transformation. With permission: H. C. Hasselbalch [12]. AML: acute myeloid leukemia; ET: essential thrombocythemia; JAK: Janus kinase; PPV-MF: post-polycythemia vera; and PV: polycythemia vera.